Influence of cardiopulmonary bypass on the interaction of recombinant factor VIIa with activated platelets.
Recombinant factor VIIa (rFVIIa) interacts preferentially with coated platelets characterized by a high exposure of phosphatidyl serine (PS), FV, FVIII, FIX, and FX binding, and fibrinogen. Cardiopulmonary bypass (CPB) is known to impair platelet function. In this study, the influence of CPB on formation of coated platelets and the interaction of rFVIIa with the platelets were studied. Blood was either exposed to a closed CPB circuit or obtained from patients undergoing CPB-assisted cardiac surgery, and platelets were analyzed by flow cytometry with and without dual agonist stimulation with thrombin and a GPVI collagen receptor agonist known to induce coated platelet formation. Platelets circulated within a closed CPB circuit did not spontaneously form coated platelets. Dual agonists stimulation caused formation of coated platelets at a reduced level compared to pre-CPB level (51 +/- 21% vs. 80 +/- 17% before CPB, p < .001). The rFVIIa interaction with the coated platelets was not impaired after CPB. Platelets isolated from patients undergoing CPB-assisted cardiac surgery also formed coated platelets only after dual agonist stimulation but to the same level as before surgery (76 +/- 8% vs. 83 +/- 14% before surgery, p = .17, n = 10). rFVIIa interaction with the coated platelets was not impaired after surgery. No spontaneous rFVIIa-binding platelets were found. The data indicate that CPB exposure in vivo does not compromise the platelet-dependent effects of rFVIIa either by spontaneous formation of coated platelets, thereby limiting the risk of systemic coagulation, or by impairing rFVIIa interaction with the agonist-induced coated platelets, thereby retaining the hemostatic potential of rFVIIa after CPB.
Kjalke
Marianne
M
Hemostasis Biology, Novo Nordisk A/S, Måløv, Denmark.
Runge
Marx
M
Rojkjaer
Rasmus
R
Steinbruchel
Daniel
D
Johansson
Pär I
PI
D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D003627:Data Interpretation, Statistical; D015942:Factor VIIa / Q000494:pharmacology*; D005340:Fibrinogen / Q000378:metabolism; D005434:Flow Cytometry; D006355:Heart-Lung Machine; D006801:Humans; D019007:P-Selectin / Q000378:metabolism; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology
D019007:P-Selectin; D011994:Recombinant Proteins; D005340:Fibrinogen; C103587:recombinant FVIIa; D015942:Factor VIIa
Curr Hematol Rep. 2004 Sep;3(5):338-43
15341700
J Thromb Haemost. 2007 Apr;5(4):774-80
17229056
Blood. 1993 Jul 1;82(1):107-17
7686785
N Engl J Med. 2005 Feb 24;352(8):777-85
15728810
Intensive Care Med. 2004 Oct;30(10):1873-81
15278267
Anesthesiology. 2004 Feb;100(2):225-33
14739793
ASAIO J. 1993 Jul-Sep;39(3):M550-3
8268596
Br J Anaesth. 2005 Nov;95(5):596-602
16183679
Ann Thorac Surg. 1998 Dec;66(6):2145-52
9930521
Biochem Biophys Res Commun. 2004 Jul 23;320(2):303-10
15219827
Transfusion. 2005 Jan;45(1):26-34
15647015
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):861-6
15653564
Ann Thorac Surg. 2001 Nov;72(5):S1821-31
11722116
Pediatr Crit Care Med. 2004 May;5(3):246-50
15115562
Lancet. 2003 Jan 18;361(9353):201-5
12547542
Semin Hematol. 2001 Oct;38(4 Suppl 12):6-9
11735103
J Trauma. 2005 Jul;59(1):8-15; discussion 15-8
16096533
Perfusion. 1996 Sep;11(5):401-6
8888063
Eur Spine J. 2004 Oct;13 Suppl 1:S83-8
15160317
Br J Haematol. 1997 Dec;99(3):542-7
9401063
JAMA. 2006 Jan 18;295(3):293-8
16418464
J Thromb Haemost. 2005 Sep;3(9):2081-8
16102115
Paediatr Anaesth. 2005 Mar;15(3):235-40
15725322
J Thromb Haemost. 2005 Oct;3(10):2185-92
16194197
Drugs. 2005;65(8):1161-77
15907148
J Lab Clin Med. 1993 Apr;121(4):579-87
8454940
Blood. 2000 Mar 1;95(5):1694-702
10688826